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ABSTRACT 
Transdermal patch is a medicated adhesive patch that is placed on the skin to deliver the drug through the skin in order to achieve 
systemic absorption of drug at a predetermined rate over a prolonged period of time. The amalgamation of polymer and 
pharmaceutical sciences led to the introduction of polymer in the design and development of drug delivery systems. Polymeric 
delivery systems are mainly intended to achieve controlled or sustained drug delivery. Polysaccharides fabricated into hydrophilic 
matrices remain popular biomaterials for controlled-release dosage forms and the most abundant naturally occurring biopolymer is 
cellulose; thus, hydroxypropyl methylcellulose (HPMC), hydroxypropyl cellulose (HPC), microcrystalline cellulose (MCC) and 
ethyl cellulose (EC) can be used for production of controlled transdermal drug delivery systems (TDDS). This paper assembles the 
current knowledge on the structure and chemistry of cellulose, and in the development of innovative cellulose esters and ethers for 
controlled release TDDS. In addition, bacterial cellulose applications through chemical modiﬁcation as a new TDDS will be 
discussed. 
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INTRODUCTION  
Transdermal drug delivery (TDD) represents an 
attractive alternative to oral delivery of drugs and is 
poised to provide an alternative to hypodermic injection 
too.
1
 TDD is defined as self-contained, discrete dosage 
forms which, when applied to the intact skin, deliver the 
drug, through the skin at controlled rate to the systemic 
circulation.
2,3
 
Advances in transdermal delivery systems can be 
categorized as undergoing three generations of 
development from the first generation of systems that 
produced many of today’s patches by judicious 
selection of drugs that can cross the skin at therapeutic 
rates with little or no enhancement; through the second 
generation that has yielded additional advances for 
small molecule delivery by increasing skin permeability 
and driving forces for transdermal transport; to the third 
generation that will enable transdermal delivery of 
small molecule drugs, macromolecules (including 
proteins and DNA) and virus based/other vaccines 
through targeted permeabilization of the skin’s stratum 
corneum.
1
 
The amalgamation of polymer and pharmaceutical 
sciences led to the introduction of polymer in the design 
and development of drug delivery systems.
2
 Polymeric 
delivery systems are mainly intended to achieve 
controlled or sustained drug delivery. Polysaccharides 
fabricated into hydrophilic matrices remain popular 
biomaterials for controlled-release dosage forms and the 
most abundant naturally occurring biopolymer is 
cellulose; thus, HPMC, HPC, MCC and EC can be used 
for production of controlled TDDS. 
For the development of film forming polymeric 
solutions as TDDS the choice of a suitable polymer for 
the formulation is very important. The film former does 
not only influence the mechanical properties of the 
formed film such as flexibility or abrasion resistance, 
the adhesion to the skin (in cooperation with the 
plasticizer) or the appearance of the film (transparency, 
smoothness, gloss) but affects also the drug permeation 
from the film into the skin. Depending on their 
chemical properties, polymers and drugs can interact in 
different ways, for example by ionic forces, hydrogen 
bonding or through the degree of solubilization of the 
drug in the polymer. An important factor with impact 
on the drug permeation can be the ability of the polymer 
to influence the physical state of the drug in the matrix 
by acting as crystallization inhibitor. When the 
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formulation is applied to the skin the drug is completely 
dissolved. With the evaporation of the solvent the drug 
concentration within the formulation rises which 
increases the thermodynamic activity of the drug in the 
formulation and with it the drug flux.
4,5
 
BACTERIAL CELLULOSE ON TDDS  
Silva et al. (2014) explored bacterial cellulose (BC) 
membranes as novel nanostructured transdermal 
delivery systems for diclofenac sodium salt.
6
 Wei et al. 
(2011) obtained BC dry ﬁlms after immersion in 
benzalkonium chloride and observed the drug effects 
lasting for at least 24 h against contaminated wound 
ﬂora such as Staphylococcus aureus and Bacillus 
subtilis.
7
  
BC ﬁbres with silver nanoparticles have successfully 
produced up to 99.99% antibacterial activity against 
Escherichia coli and S. aureus.
8
 The use of silver 
nanocomposites with BC has been endorsed as a 
promising strategy in which antibacterial properties are 
required.
9
 
The S-enantiomer of propranolol has been released from 
a composite layer of BC membrane with methacrylate, 
and applied to transdermal application where primary 
control of drug release came from the parent BC 
membrane.
10
 These encouraging results indicated that 
BC, which acts as a base for molecular imprinting 
networks, are amendable to treatments like reactive 
pore ﬁlling that make BC suitable for chiral 
applications.  
BC could also be used in conjunction with a conducting 
polymer, such as polyaniline, which has been reported 
to have electro-conductivity, and thus, has the potential 
to act as electrically stimulated drug delivery device. 
The product was formed by polymerisation of aniline 
on single side of the BC membrane and this composite 
acted as super capacitor.
11
 
This property could therefore be combined with 
biocompatibility, biodegradability and improved 
mechanical properties of BC, although the 
hydrophobicity of the conducting polymers needs to be 
modiﬁed for successful protein entrapment. Considering 
this, iontophoresis (drug delivery by electric potential) 
can be applied to expand the application of BC. In this 
view, BC was combined with multi walled carbon 
nanotubes and electro-conductivity was increased up to 
1.4 × 10
−1
 S/cm.
12, 13
 
HYDROXYPROPYL METHYLCELLULOSE 
(HPMC) 
The controlling regime for HPMC and drug release 
from a swollen matrix includes both the gelled matrix 
and the gelled matrix-bulk solution interface. The 
transport hindrance within the gelled matrix is dictated 
by the structure and composition of the gelled matrix.  
On the other hand, release kinetics at the gelled matrix-
bulk solution interface plays a significant role as well.
14
 
HPMC, a hydrophilic swellable polymer widely used in 
oral controlled drug delivery, also has been explored as 
a matrix former in the design of patches of propranolol 
hydrochloride. HPMC has been shown to yield clear 
films because of the adequate solubility of the drug in 
the polymer. Matrices of HPMC without rate-
controlling membranes exhibited a burst effect during 
dissolution testing because the polymer was hydrated 
easily and swelled, leading to the fast release of the 
drug.
15
 
Garala et al. (2009) designed to formulate a transdermal 
therapeutic system of tramadol HCl using a polymeric 
(HPMC) matrix film. Several diffusion pathways 
created due to the blend of the polymers to generate 
overall desired steady and sustained drug release from 
the patches. The manner by which drug release in most 
of the controlled/sustained release devices including 
transdermal patches is governed by diffusion. Diffusion 
is naturally a probabilistic process described by the 
random walk of molecules. The polymer matrix has a 
strong influence on the diffusivity as the motion of a 
small molecule is restricted by the three dimensional 
network of polymer chains.
14,16
 
When this matrix patch comes into contact with an in-
vitro study fluid, the fluid is absorbed into the polymer 
matrix and this initiates HPMC chain dissolution 
process in the matrix. HPMC chain dissolution from the 
matrix surface involves two distinguishable steps. The 
first step involves changes in entanglement of 
individual drug molecules at the matrix surface, which 
depends on the rate of hydration. The second step 
involves the shift of this molecule from the surface 
across the diffusion membrane initially to the surface 
and then to the bulk of the in vitro study fluid. It is well 
known that the addition of hydrophilic component to an 
insoluble film former leads to enhance its release rate 
constant. This may be due to dissolution of the aqueous 
soluble fraction of the film, which leads to creation of 
pores and decrease of mean diffusion path length of the 
drug molecule to be released.
14, 17
 
Monolithic matrix transdermal systems containing 
tramadol HCl were prepared by Garala et al. (2009) 
using various ratios of the polymer blends of HPMC 
and Eudragit S (ES) 100 with triethylcitrate as a 
plasticizer. The moisture content of the prepared 
transdermal film was low, which could help the 
formulations remain stable and from being a completely 
dried and reduce brittleness during storage. It was 
observed that initially there was rapid release of drug 
from the patch. This rapid drug release (burst effect) 
from the prepared transdermal patch might be due to 
rapid dissolution of the surface drug. The burst release 
can be useful for dermal penetration of drugs. When the 
drug is released from the matrix in such a way that the 
rate of release of the drug remains constant, the release 
kinetics of the drug are believed to follow a zero-order 
kinetics. The release profile of the dissolved drug can 
generally be described by the Fick’s law and predicted 
that the cumulative mass released is proportional to the 
square root of time.
16
  
Orally Clopidogrel bisulfate has a short elimination 
half-life (7-8 hrs), low oral bioavailability (50%) 
undergoes extensive first pass metabolism (85%) and 
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frequent high doses (75 mg) are required to maintain the 
therapeutic level as a result, dose development toxic 
effect. TDDS of Clopidogrel bisulfate formulated and 
evaluated by using various polymers such as HPMC, 
PVP and EC by solvent evaporation technique for 
improvement of bioavailability of drug and reducing 
toxic effects. The result of diffusion study showed that 
formulation, F2 (HPMC and PVP) showed maximum 
release of 90.06 % in 24 h. Based on the drug release 
and physicochemical values obtained the formulation 
F2 is considered an optimized formulation which 
showed higher percentage of drug release of 90.06 % in 
24 h. The developed transdermal patches increase the 
therapeutic efficacy and reduced toxic effect of 
Clopidogrel bisulfate.
18
 
The matrix type TDDS of LRDP (Lercanidipine 
Hydrochloride) were prepared by solvent evaporation 
technique. Formulations were composed of HPMC and 
Eudragit RL100 (ERL). All the six formulations carried 
10 mg of LRDP/patch area, 8 % v/w of d-limonene as a 
penetration enhancer, 20 % v/w of propylene glycol as 
plasticizer in methanol and dichloromethane as solvent 
system. All the formulations exhibited satisfactory 
physicochemical characteristics. By fitting the data into 
zero order, first order and Higuchi model, it was 
concluded that drug release from matrix films followed 
Higuchi model and the mechanism of the drug release 
was diffusion mediated. The patches were seemingly 
free of potentially hazardous skin irritation. The patches 
composed of ERL, HPMC (1.5:8.5) with 8 % v/w 
limonene as penetration enhancer may be selected for 
the development of TDDS of LRDP for potential 
therapeutic use by using a suitable adhesive layer and 
backing membrane.
19
 
ETHYLCELLULOSE (EC) 
EC is a water-insoluble polymer used in controlled-
release dosage forms. In the absence of polymer 
swelling ability, EC compatibility becomes a key factor 
in such systems, because release kinetics would depend 
largely on the porosity of the hydrophobic compact. 
Although EC is considered insoluble, it can take up 
water. This is because of its hydrogen bonding 
capability with water due to the polarity difference 
between the oxygen atom and the ethyl group of the 
polymer.
20
 
When the active agent (drug) is released from the 
matrix in such a way that the rate of release of the drug 
remains constant, the release kinetics of the drug are 
believed to follow a zero-order kinetics. The 
formulation studied by Mukherjee et al (2005) appeared 
to follow similar patterns of drug release proﬁles, i.e. 
initially apparent zero-order and then ﬁrst order release 
kinetics. Initially for ﬁrst few hours the drug release, 
kinetic patterns followed zero-order drug release 
proﬁles and with the enhancement of time the release 
proﬁles gradually changed into the concentration 
dependent ﬁrst order release kinetics. The drug polymer 
matrix initially ensured constant concentration of drug 
in in vitro study ﬂuid, but afterwards, concentration 
dependent release kinetic made the reaction towards the 
ﬁrst order kinetic.21 
Drug release from a porous, hydrophobic polymeric 
drug delivery system occurs when the drug comes into 
contact with the release media, subsequently dissolves 
and diffuses through media filled pores. Thus, the 
geometry and structure of the pore network are 
important in this process. The Higuchi model has been 
reported to fail at drug loading levels below the 
percolation threshold. Below the percolation threshold, 
incomplete drug release is observed presumably due to 
limited accessibility of many drug particles to the 
dissolution medium since they are encapsulated by 
water insoluble polymeric materials.
22
 
When the matrix patch which contains EC comes into 
contact with an in vitro study ﬂuid, thermodynamically 
compatible with the polymer, the ﬂuid is absorbed into 
the polymer matrix and this initiates polymer chain 
dissolution process in the matrix. Polymer chain 
dissolution from the matrix surface involves two 
distinguishable steps. The ﬁrst step involves changes in 
entanglement of individual drug molecules at the matrix 
surface, which depends on the rate of hydration. The 
second step involves the transport of this molecule from 
the surface across the skin, adjacent to the matrix patch, 
initially to the surface and then to the bulk of the in 
vitro study ﬂuid. Molecular diffusion through polymers 
is an effective, simple and reliable means of attaining 
sustained/controlled release of a variety of active 
agents.
21
 
Gupta and Mukherjee (2003) select a suitable 
formulation for the development of TDDS of diltiazem 
hydrochloride. Transdermal patches of the drug, 
employing diﬀerent ratios of polymers, EC, and PVP 
were developed and evaluated for the potential drug 
delivery using depilated freshly excised abdominal 
mouse skin. The cumulative amount of drug was found 
to be proportional to the square root of time, i.e., 
Higuchi kinetics. From this study, it was concluded that 
the ﬁlms composed of PVP: EC (1:2) should be selected 
for the development of transdermal drug-delivery 
system of diltiazem hydrochloride, using a suitable 
adhesive layer and backing membrane, for potential 
therapeutic use.
23
 
EC and PVP matrix films with 30% dibutyl phthalate as 
a plasticizer have been fabricated to deliver diltiazem 
hydrochloride and indomethacin. The addition of 
hydrophilic components such as PVP to an insoluble 
film former such as ethyl cellulose tends to enhance its 
release-rate constants. This outcome can be attributed to 
the leaching of the soluble component, which leads to 
the formation of pores and thus a decrease in the mean 
diffusion path length of drug molecules to release into 
the dissolution medium. The result is higher dissolution 
rates. Substances such as PVP act as antinucleating 
agents that retard the crystallization of a drug. Thus 
they play a significant role in improving the solubility 
of a drug in the matrix by sustaining the drug in an 
amorphous form so that it undergoes rapid 
solubilization by penetration of the dissolution 
medium.
24
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Mukherjee et al. (2005) developed a suitable matrix 
type TDDS of dexamethasone using blends of two 
different polymeric combinations, PVP and EC and 
Eudragit with PVP. All the formulations were found to 
be suitable for formulating in terms of physicochemical 
characteristics and there was no signiﬁcant interaction 
noticed between the drug and polymers used. In vitro 
dissolution studies showed that the drug distribution in 
the matrix was homogeneous and the SEM photographs 
further demonstrated this. The formulations of PVP: EC 
provided slower and more sustained release of drug 
than the PVP:Eudragit formulations during skin 
permeation studies and the formulation PVP:EC (1:5) 
was found to provide the slowest release of drug. Based 
on the above observations, it can be reasonably 
concluded that PVP-EC polymers are better suited than 
PVP-Eudragit polymers for the development of TDDS 
of dexamethasone.
21
 
HPMC WITH EC 
EC blended with HPMC are frequently used in drug 
delivery systems. By using polymer combinations, 
formulators may be able to develop sustained-release 
drug dosage forms with better performance than is 
shown by the individual polymer components. Various 
polymer blends have been studied in order to achieve 
the desired release kinetics. The presence of more than 
one polymer in a formulation may result in a spatial 
configuration, but it is also possible that a polymer 
additive may become part of the gel network. The 
externally adsorbed water in the insoluble polymers 
(EC) can assist in the formation of liquid bridges 
between the particles. Any soluble component in the 
formulation could dissolve in these liquid bridges and 
thus assist in the formation of solid bridges between the 
particles on drying, which would sustain the granule 
integrity and alter the physicochemical properties of the 
matrixing agent. These polymers can be expected to 
experience an aqueous environment in production and 
in vivo. The water-polymer and polymer-polymer 
interactions and their distribution and/or configuration 
within a formulation are critical to their applications in 
wet massing techniques.
20 
Transdermal patches control 
the delivery of drugs at controlled rates by employing 
an appropriate combination of hydrophilic and 
lipophilic polymers.
25
 
The mechanical properties of free films prepared from 
various ratios of HPMC and EC with and without 
plasticizer were characterized. The film made from 
HPMC alone without plasticizer was very hard and 
brittle, expressed by the very high Young’s modulus 
value. Plasticization of hydrophilic polymers like 
HPMC with hydrophobic plasticizer provided the 
higher strength but lower elongation film as compared 
to those of the hydrophilic polymer film plasticized 
with hydrophilic plasticizer. Addition of EC into the 
HPMC film resulted in the lower ultimate tensile 
strength, percent elongation at break and Young’s 
modulus. The molecular structure of EC contains long 
chain of AGU linked together with acetal linkage. This 
kind of structure is hydrophobic in nature. Therefore, 
the presence of EC might have been responsible for the 
lower strength and elongation when compared to 
HPMC alone.
26
 
The matrix TDDS bearing naproxen was fabricated 
using various concentration ratios of EC and HPMC. 
The drug was uniformly distributed in the polymer 
films and drug content was found to be 98.6% to 99.0% 
per cm
2
 in the TDDS. Films of lipophilic-hydrophilic 
polymers in various proportions were studied.  The 
combination of EC and HPMC in a ratio of 2:8 and 4:6 
showed highest cumulative drug release. Increasing the 
proportion of HPMC concentration increases the 
cumulative amount release. From the release studies it 
was observed that by increasing the proportion of 
HPMC tend to increase the cumulative amount of drug 
release. This increased release rate may be due to higher 
hydrophilic nature of HPMC. Due to its high 
hydrophilicity it absorbs water and swells resulting in 
the more release of drug from the patches. The decrease 
in drug release rate from films containing more 
lipophilic polymer combination may be attributed to the 
relatively hydrophobic nature of polymer which has less 
affinity for water, this result in decrease in 
thermodynamic activity of the drug in the film and 
decreased drug release.
27
 
Limpongsa and Umprayn (2008) prepared the suitable 
polymeric films for the development of diltiazem 
hydrochloride TDDS. HPMC and EC used as 
hydrophilic and hydrophobic film formers, respectively. 
The films composed of 8:2 HPMC/EC, 30% dibutyl 
phthalate (DBP) and 10% Isopropyl myristate (IPM), 
Isopropyl palmitate (IPP) or tween 80 loaded with 25% 
diltiazem HCL selected for manufacturing transdermal 
patch by using a suitable adhesive layer and backing 
membrane.
26
  
Transdermal patches of Promethazine hydrochloride 
and Ondensetron hydrochloride with HPMC and EC 
was prepared by solvent evaporation technique. The 
patch was found to be efficacious, safe, stable and 
nonirritant to skin. The establishment of steady state 
levels in vitro for 48h showed the clear advantage of 
transdermal patches over current modes of 
administration. Drugs like promethazine Hydrochloride 
and Ondensetron Hydrochloride were formulated into 
matrix type patches in an attempt to solve the problems 
associated with oral administration. The drug release 
was found to be linear and follow the Higuchi diffusion 
equation. The release kinetics of Promethazine 
Hydrochloride and Ondensetron Hydrochloride 
formulations follows zero order and first order kinetics. 
Hixon Crowell equation also found to be linear, these 
indicating that the release from the patches was by both 
diffusion and erosion methods.
28
 
HPMC and EC films were prepared using DBP as 
plasticizer with eighteen different combinations of these 
three polymers by solvent evaporation technique. 
Polyvinyl alcohol was used to prepare the backing 
membrane. Formulations containing higher proportion 
of hydrophilic polymers blended with lower proportions 
of hydrophobic polymer were found less consistent in 
comparison to the patches comprised of higher 
proportion of hydrophobic polymer. Skin irritation 
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study indicated that the prepared patches were having 
no effect of irritation upon administration and is safe for 
topical application. The scanning electron microscopic 
photographs showing formation of pores onto the 
surface of the film after skin permeation study was due 
to the exhaustion of the contained drug. It is evident that 
higher proportions of hydrophilic polymers (HPMC) in 
formulations resulted in an enhanced permeation of the 
contained drug. Whereas permeation of the contained 
drug was opposed when there was least concentration of 
hydrophilic polymers blended with highest 
concentration of hydrophobic polymer (EC).
29
 
HYDROXYPROPYLCELLULOSE (HPC) 
Repka and McGinity (2001) investigated the in vivo 
bioadhesive properties of HPC ﬁlms containing seven 
polymer additives on the epidermis of 12 human 
subjects, including two ethnic sub-groups. HPC ﬁlms 
containing polyethylene glycol (PEG 3350) alone, 
Vitamin E TPGS (TPGS) 5%, sodium starch glycolate 
5%, Eudragit E-100 5%, carbomer 974P and 971P 5%, 
and polycarbophil 5%, all with and without plasticizer, 
were prepared by hot-melt extrusion utilizing a 
Randcastle Microtruder (Model [RCP-0750). In vivo, 
the TPGS-incorporated ﬁlm exhibited a two-fold 
increase in FA when compared to the control ﬁlm 
containing the PEG 3350 5%. The carbomer 971P and 
polycarbophil containing ﬁlms were determined to have 
the highest FA and EAF, and the lowest MA of all ﬁlms 
tested. The ﬁlm containing carbomer 971P had a higher 
FA than the ﬁlm containing 974P. In addition, ﬁlms in 
one ethnic sub-group exhibited higher FA and EAF than 
the other. Force–deﬂection proﬁles obtained from these 
experiments indicate that the force of adhesion, 
elongation at adhesive failure and modulus of adhesion 
are a function of the polymer additive in the HPC 
extruded ﬁlms. The incorporation of carbomer 971P and 
a polycarbophil into HPC ﬁlms increased bioadhesion 
signiﬁcantly when compared to the ﬁlm containing HPC 
and PEG 3350. Differences in FA and EAF were 
discovered between two ethnic sub-groups tested.
25
 
Schroeder et al. (2007) evaluated the potential of these 
systems for TDDS the permeation of ethinylestradiol 
from four formulations with different polymers was 
tested across heat separated human epidermis. The film 
forming solution showed a higher ethinylestradiol 
permeation through heat separated human epidermis 
than the commercial EVRA® patch in vitro and 
achieved measurable plasma concentrations of 
ethinylestradiol in vivo in pigs. The polymers used in 
the tested formulations were HPC, ammonio 
methacrylate copolymer type A (Eudragit® RL PO), 
polyurethane-14 and AMP-acrylates copolymer 
(DynamX®) and silicon gum (SGM 36).
30
 
CELLULOSE ACETATE (CA)  
When CA is used as a rate controlling membrane 
material for TDDS, generally requires plasticizers to 
improve its mechanical property. A plasticizer is 
supposed to weaken the intermolecular forces between 
the polymer chains, resulting in a softened and flexible 
polymer matrix. Thus, drug permeability through the 
membranes may also be affected by the addition of a 
plasticizer. The weight loss of membranes versus 
temperature is no detectable degradation below 200
o
C. 
PEG is a non-solvent for cellulose acetate and can 
facilitate the phase inversion of the polymer solution. 
Faster phase inversion induced by the addition of PEG 
leads to more porous membrane structures. The 
morphology difference between the top surface and 
bottom surface may also arise from the difficulty in 
solvent transferring during the membrane formation.
31
 
The  plasticizer  will  interpose  itself  between  the  
polymer  chains  and  interact  with the  forces  held  
together  by  extending  and  softening  the polymer  
matrix. These  are incorporated  into  the  films  for  
various  reasons  such  as  to reduce  brittleness,  impart  
flexibility,  increase  strength  and also  to  improve  
adhesiveness  of  the  film  with  other  surfaces  or  
membranes. Plasticizer shifts the glass transition 
temperature to lower temperature and is an important 
formulation factor. PEG 400, DBP and PG at a 
concentration of 40 % w/w of polymer were used as a 
plasticizer. Preliminary experiments indicated lower 
concentrations were found to give rigid and brittle 
patches whereas higher concentrations gave soft 
patches. So plasticizers at a concentration of 40 % was 
found to give good flexible patches and easily removed 
from the mercury surface without any rupture.
32
 
Transdermal patches composed of highest proportion of 
hydrophobic polymer (CA) blended with lowest 
proportion of hydrophilic polymer (PVP and HPMC) 
were found to have low moisture content. This helps 
them to remain stable and prevent from being a 
completely dried and brittle film. Similarly, a low 
moisture uptake protects the material from microbial 
contamination and limits the bulkiness of the patches.
29
 
Rao and Diwan (1997) studied CA free  films  casted  
from  chloroform  solution  containing  different  
plasticizers to  develop  a  suitable  rate  controlling  
membrane  for  transdermal  use. DBP, PEG and PG 
were  used  as  plasticizers  at  a  concentration  of  40%  
w/w  of  dry  polymer  weight. Water  vapor  
transmission  and  drug  diffusion  through  the  free  
films  followed  zero order  kinetics  and  decreased  
with  increasing  the  film  thickness.  The films 
plasticized  with  PEG showed  higher  permeability  for  
both drugs  compared  with  other  films.  The  order  of  
decrease  of  permeability  of  plasticized  films  with  
plasticizers  is  PEG > PG  >  DBP. Diffusion  of  drugs  
through  the  free  films  of  CA  was  extended  over  a  
longer  period  of  time  at  a  controlled  rate  and  thus,  
these  can  be  used as  rate  controlling  membranes  for  
the  development  of  a  transdermal  drug  delivery  
system.
33
   
Wang (2002) studied on CA membrane used as 
controlled release in TDDS of scopolamine. In this 
study, the CA membranes were cast with acetone as a 
solvent at 22 and 40 C. PEG was used as a pore-
forming agent. It was observed that the drug permeation 
through the CA membranes was obviously affected by 
the incorporated PEG content and formed membrane 
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morphology. There was no drug flux from the CA 
membranes prepared without PEG. An increased PEG 
content resulted in a faster scopolamine release due to a 
more porous structure created. Both the membrane 
fabrication temperature and the PEG content can affect 
the thermal, mechanical and morphological properties 
of the resultant membranes. With the optimized 
fabrication conditions, linear in vitro release profiles of 
scopolamine over 3 days were achieved. The 
membranes developed would be useful for transdermal 
delivery of drugs.
31
 
HPMC: PVP polymer combination with DBP as 
plasticizer has maximum folding endurance while CA: 
PEG4000 with PEG400 showed least folding 
endurance. The tensile strength of the patches was 
found to vary with the nature of polymer and 
plasticizer. A soft and weak polymer is characterized by 
low tensile strength and low elongation, a hard and 
brittle polymer is defined by a moderate tensile strength 
and low elongation, and a soft and tough polymer is 
characterized by moderate tensile strength and high 
elongation, whereas a hard and tough polymer is 
characterized by high tensile strength and high 
elongation. Polymer combination CA: PVP plasticized 
with DBP possessed high tensile strength while 
polymers plasticized with Eudragit RL100: 
EudragitRS100 plasticized with PEG possessed low 
tensile strength. Among the plasticizers the tensile 
strength of the patches decreased in the following order 
DBP>PG>PEG400. Patches require certain amount of 
hardness to withstand the mechanical shocks in 
handling, packaging and at the time of application. The 
hardness of the patch varied from 132 g to 307 g, 
Surface pH varied 5.1 to 6.0 indicating that no irritation 
will occur on the skin after applications of the patches.
32
 
Table 1 also shows the review of cellulose derivatives 
used in TDDS.  
 
Table.1 Cellulose derivatives used in TDDS 
Polymer Types of Formulations Drug 
CA film Drug free
33
 
HPC 
HPC: Eudragit E 100  
HPC: Carbopol 971P  
HPC: Polycarbophil 
Matrix Vitamin E
25
 
CA Membrane Scopolamine
31
 
EC: PVP Matrix Propranolol  
EC: PVP; Eudragit: PVP Matrix Dexamethasone
21
 
EC: PVP Matrix Propranolol  
HPC 
Eudragit RL PO  
Silicon Gum  
Acrylate copolymer  
Film  
forming  
polymeric  
solution 
Ethinylestradiol
30
 
HPMC: EC Matrix Diltiazem HCl
26
 
EC:PVP 
EC:HPMC 
Matrix Losartan
29
 
CA: HPMC 
PVP: PEG 4000 
Eudragit RL 100-RS 100  
Matrix Drug Free Patch
32
 
HPMC: Eudragit RS 100   
HPMC: Eudragit RL 100 
Matrix Venlafaxine  
HPMC: Eudragit RL 100  
Bilayer  
Matrix 
Domperidone  
HPMC: Eudragit RL 100  Matrix Lercanidipine
19
 
HPMC, Eudragit RL 100, Chitosan  Matrix Gliclazine 
HPMC, PVP, Eudragit RS100  Matrix Valsartan  
EC: HPMC Matrix Naproxen
27
 
 
 
FUTURE PERSPECTIVES 
Transdermal route has vied with oral treatment as the 
most successful innovative research area in drug 
delivery. Since cellulose exhibits several unique 
properties, well established history in drug delivery and 
in food industry, its use in human is safe. So it is a 
good candidate in the formulation and developing a 
TDDS.  
Cellulose and its derivatives have been used to 
fabricate different drug delivery systems including 
TDD. In order to utilize the full potential of Cellulose 
and its derivatives in the broad area of drug delivery, it 
is necessary to understand their fundamental physical, 
chemical and biological properties.  
Bacterial cellulose has a great potential in TDDS due to 
its high purity and special chemical properties. But it 
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has not enough yields industrially and not economical. 
In order to meet the growing demand of BC, a robust 
and feasible industrial production and supply is crucial. 
Despite of the relatively simple fermentation process, 
new engineering processes are needed to produce 
desired BC with speciﬁc material properties. Moreover, 
genetic and biochemical investigations are also 
necessary to enhance BC production at molecular 
biological level and commercial purposes. 
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